Shigenobu Bando1, Akiyoshi Nishikado1, Norikazu Hiura1, Shuntaro Ikeda2, Akiyoshi Kakutani3, Katsuhito Yamamoto4, Noriyoshi Kaname5, Masahiko Fukatani5, Yuichiro Takagi6, Kazushi Yukiiri7, Yamato Fukuda8, Yutaka Nakaya9. 1. Department of Arrhythmia, Kagawa Prefectural Shirotori Hospital, Kagawa, Japan. 2. Department of Cardiology, Uwajima City Hospital, Ehime, Japan. 3. Department of Cardiology, Yoshinogawa Medical Center, Tokushima, Japan. 4. Department of Cardiology, Kochi Medical Center, Kochi, Japan. 5. Department of Cardiology, Chikamori Hospital, Kochi, Japan. 6. Department of Cardiology, KKR Takamatsu Hospital, Kagawa, Japan. 7. Takamatsu Heart Clinic, Kagawa, Japan. 8. Fukuda Heart and Digestive Medical Clinic, Kochi, Japan. 9. Department of Nutrition and Metabolism, the University of Tokushima, Japan. Electronic address: nakaya.y@tokushima-u.ac.jp.
Abstract
BACKGROUND: The Shikoku Rivaroxaban Registry Trial (SRRT) is a retrospective survey of the use of rivaroxaban for stroke prevention in elderly patients in Shikoku, Japan. METHODS: The SRRT enrolled 1339 patients from 8 hospitals. Patients were divided into two groups according to their age, the extreme elderly group (453 patients aged ≧80 years) and the control group (886 patients aged <80 years). RESULTS: In the extreme elderly group, 41.5% of the patients had low body weight (<50kg) and 65.1% had abnormal renal function (creatinine clearance <50ml/min). The mean CHADS2, CHA2DS2-VASc, and HAS BLED scores were 2.7, 4.4, and 2.3, respectively. There were 333 (73.5%) patients who met the dosing criteria, and of these patients, 81.2% received rivaroxaban 10mg daily. Thromboembolic events occurred in 4 patients (0.94%/person year) and intracranial hemorrhage occurred in 4 patients (0.89%/person year). The incidence of these events was not significantly different from the control group. In addition, all patients with cerebral infarction had been treated with a smaller dose of rivaroxaban than recommended by the dosing criteria, suggesting that dosing criteria should be adhered to. CONCLUSION: These results suggest that rivaroxaban is effective and safe in extreme elderly patients with atrial fibrillation.
BACKGROUND: The Shikoku Rivaroxaban Registry Trial (SRRT) is a retrospective survey of the use of rivaroxaban for stroke prevention in elderly patients in Shikoku, Japan. METHODS: The SRRT enrolled 1339 patients from 8 hospitals. Patients were divided into two groups according to their age, the extreme elderly group (453 patients aged ≧80 years) and the control group (886 patients aged <80 years). RESULTS: In the extreme elderly group, 41.5% of the patients had low body weight (<50kg) and 65.1% had abnormal renal function (creatinine clearance <50ml/min). The mean CHADS2, CHA2DS2-VASc, and HAS BLED scores were 2.7, 4.4, and 2.3, respectively. There were 333 (73.5%) patients who met the dosing criteria, and of these patients, 81.2% received rivaroxaban 10mg daily. Thromboembolic events occurred in 4 patients (0.94%/person year) and intracranial hemorrhage occurred in 4 patients (0.89%/person year). The incidence of these events was not significantly different from the control group. In addition, all patients with cerebral infarction had been treated with a smaller dose of rivaroxaban than recommended by the dosing criteria, suggesting that dosing criteria should be adhered to. CONCLUSION: These results suggest that rivaroxaban is effective and safe in extreme elderly patients with atrial fibrillation.